Dr. Blum is a pharmaceutical medicine expert with hands on experience in various aspects of drugs and medical devices development process, from regulatory, pre-clinical and clinical development aspects to business development.
Dr. Blum has earned his MD and PhD degrees from the Technion, Israel Institute of Technology and hold a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine, University of Basel, Switzerland. He has over 15 years of experience in design and leadership of clinical trials including large scale randomized trials as well as development of drugs, medical devices, biologics and advanced therapies, both in the academic and industrial arenas. Dr. Blum hold the position of VP Clinical Affairs of Medgenics, a biotech company developing gene therapy platform for orphan diseases. Before joining Medgenics, Dr. Blum was the Founder and CEO of Haptocure Ltd. an Israeli biomedical start-up company developing a pharmacogenomics package of a test and a drug in Diabetes with a technology licensed from the Technion and developed in Prof. Andrew Levy’s lab around the Haptoglobin gene polymorphism. Before that Dr. Blum was the Global Medical Director of Pharma Brains AG, a Swiss based international contract research organization (acquired by Medpace Inc.), and served as consultant in drugs and medical device development to various companies. Dr. Blum was the Medical Director of the Research and Development unit of the Rambam Medical Center in Haifa. Dr. Blum won the 2006 Young Investigator Award of the American College of Cardiology as well as H.N. Neufeld Award for Best Original Research, awarded by the Israel Heart Society. Dr. Blum is an adjunct Senior Lecturer in the Technion Faculty of Medicine. He is the author of 28 papers published in leading peer reviewed journals, a book chapter and 2 patents and serves as a reviewer of several journals. He was also an Expert Evaluator for the European Commission, Directorate General for Research and Innovation, FP7 HEALTH framework and now for the new Horizon 2020 framework.
Dr. Blum’s main research interest is in elucidating mechanisms underlining the increased CVD morbidity and mortality in Diabetes, and utilizing the Haptoglobin allelic polymorphism in pharmacogenomics.

Share The Story